Drug
Spesolimab
Spesolimab: highest development phase Post-Market, developed by LEO Pharma. 3 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- LEO Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| Spesolimab NCT06013969 | Post-Market | Generalized Pustular Psoriasis |
| Spesolimab NCT06624670 | Phase 3 | Pyoderma Gangrenosum |
| Spesolimab NCT03886246 | Phase 2 | Generalized Pustular Psoriasis |
Latest
No recent events.
Follow Spesolimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.